We have studied the onset and duration of action of rocuronium 0.6 mg kg 91 in patients receiving therapy for more than 1 month with beta-receptor blocking drugs (n:16), calcium entry blocking drugs (n:17) or anticonvulsant drugs (n:14) and compared these data with those from a control group (n:27). Anaesthesia comprised fentanyl, propofol infusion and nitrous oxide in oxygen. Neuromuscular block was monitored by measuring the force of contraction of the adductor pollicis muscle in response to train-of-four (TOF) stimulation. There were no significant differences in onset times between the four groups (mean 62-76 s). Mean times to 25% recovery of T1 (first response in the TOF) and of the TOF ratio of 0.7 were 38 (SD 15) and 58 (22) min, 36 (8) and 61 (19) min, 40 (11) and 68 (22) min, and 25 (6) and 35 (9) min in the control, beta-blocker, calcium entry blocker and anticonvulsant groups, respectively (P:0.01 between the anticonvulsant and other groups). We conclude that chronic therapy with anticonvulsant drugs reduces the duration of action of rocuronium. (Br. J. Anaesth. 1997; 78: 90-91) Key words Neuromuscular block, rocuronium. Interactions (drug). Sympathetic nervous system, adrenergic block. Calcium channel block. Anticonvulsants.
Rocuronium is a new non-depolarizing neuromuscular blocking agent with an intermediate duration of action, but with a rapid onset of action. 1 Previous experimental or clinical studies have shown significant alterations in the effects of neuromuscular blocking agents by anticonvulsant, beta-receptor antagonist and calcium channel blocking drugs or in those receiving chronic therapy with these agents. [2] [3] [4] Knowledge of these interactions may be important to enable the anaesthetist to avoid delays and risk to the patient from over-curarization, or to anticipate the need for more frequent dosing. The aim of this study was to investigate any clinically important effects of therapy with these three commonly prescribed groups of drugs on the onset and duration of action of rocuronium.
Methods and results
We studied 74 ASA I-III patients, aged 18-74 yr, with their written informed consent and approval of the Research Ethics Committee. Sixteen patients were receiving chronic therapy (for at least 1 month) with beta-receptor blocking drugs (propranolol and atenolol five each, metoprolol and bisoprolol two each, oxprenolol and celiprolol one each), 17 with calcium entry blocking drugs (nifedipine 12, diltiazem and nicardipine two each, amlodipine one), and 14 with anticonvulsant drugs (carbamazepine alone or in combination with other anticonvulsants 12, phenytoin one, sodium valproate one). Twenty seven patients in the "control" group were not receiving any of these or any other drugs known to interact with neuromuscular blocking agents.
Patients were premedicated with temazepam 10-20 mg and anaesthetized with fentanyl 1-3 g kg
91
, propofol 1-2.5 mg kg 91 followed by an infusion of propofol, and 65% nitrous oxide in oxygen. The ulnar nerve was stimulated transcutaneously with supramaximal stimuli of 0.2 ms duration in a train-of-four (TOF) sequence at 2 Hz every 12 s and the resultant force of contraction of the adductor pollicis muscle was measured and recorded using a force transducer and a neuromuscular function analyser (Myograph 2000, Biometer Ltd, Denmark). Hand skin temperature was maintained above 32ЊC.
The control responses were stabilized for approximately 10 min before administration of rocuronium 0.6 mg kg
. The times from administration of rocuronium to maximal depression of T1 (onset time) and its recovery to 25, 75 and 90% of control, and of recovery of the TOF ratio to 0.7, were recorded. Patient data were subjected to,the Kruskal-Wallis test followed by Dunn's test, if significant differences were observed. Neuromuscular data between the control and each of the study groups were subjected to the Wilcoxon test using the Hochberg-Bonferroni correction. P:0.05 was accepted as significant.
The times to onset of maximum block and recovery are shown in table 1. Onset times did not differ significantly between the groups. All patients attained 100% block. There were no significant differences in the recovery times between the control, beta-receptor blocker and calcium entry blocker groups. However, the times for recovery of T1 to 25% and of the TOF ratio to recover to 0.7 in the anticonvulsant group were significantly shorter compared with the other groups (P:0.01). The mean T1 25-75% recovery index of 9 min in this group, although shorter, was not statistically significant at the 5% level (P:0.06).
Comment
We have observed a shorter duration of action of rocuronium in patients receiving anticonvulsant therapy, as is known for many other blockers, compared with other classes of drug which caused no significant interaction. The reasons for this effect may be increased plasma protein binding of the blocker, hepatic enzyme induction or proliferation of acetylcholine receptors on the muscle membrane. 5 6 Calcium entry blocking drugs, such as verapamil, may have neuromuscular blocking effects and may cause difficulty in antagonism of block. 3 7 However, nifedipine, the drug used by the majority of patients in our study, has been shown not to interact significantly with vecuronium in humans 8 although that does not exclude the possibility of an interaction between rocuronium and verapamil.
Although there is some experimental evidence on the interaction of propranolol with neuromuscular blocking agents, it seems unlikely from our results and absence of previous clinical reports with other blockers that there is any important interaction between beta-receptor blocking and neuromuscular blocking drugs.
